154 related articles for article (PubMed ID: 28219253)
1. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Huang C; Li NM; Gao P; Yang S; Ning Q; Huang W; Li ZP; Ye PJ; Xiang L; He DX; Tan XW; Yu CY
Drug Deliv; 2017 Nov; 24(1):459-466. PubMed ID: 28219253
[TBL] [Abstract][Full Text] [Related]
2. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
[TBL] [Abstract][Full Text] [Related]
3. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
[TBL] [Abstract][Full Text] [Related]
4. Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
Chen S; Ouyang H; He D; Liu D; Wang X; Chen H; Pan W; Li Q; Xie W; Yu C
Curr Pharm Des; 2022; 28(25):2113-2125. PubMed ID: 35524673
[TBL] [Abstract][Full Text] [Related]
5. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
Xiang Y; Huang W; Huang C; Long J; Zhou Y; Liu Y; Tang S; He DX; Tan XW; Wei H; Yu CY
Mol Pharm; 2020 Sep; 17(9):3223-3235. PubMed ID: 32658485
[TBL] [Abstract][Full Text] [Related]
6. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
Yu CY; Wang YM; Li NM; Liu GS; Yang S; Tang GT; He DX; Tan XW; Wei H
Mol Pharm; 2014 Feb; 11(2):638-44. PubMed ID: 24383625
[TBL] [Abstract][Full Text] [Related]
8. L-Cysteine conjugated poly L-lactide nanoparticles containing 5-fluorouracil: formulation, characterization, release and uptake by tissues in vivo.
Mishra BJ; Kaul A; Trivedi P
Drug Deliv; 2015 Feb; 22(2):214-22. PubMed ID: 24524408
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
[TBL] [Abstract][Full Text] [Related]
10.
Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma.
Babaei M; Abnous K; Taghdisi SM; Amel Farzad S; Peivandi MT; Ramezani M; Alibolandi M
Nanomedicine (Lond); 2017 Jun; 12(11):1261-1279. PubMed ID: 28520529
[TBL] [Abstract][Full Text] [Related]
12. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
[TBL] [Abstract][Full Text] [Related]
13. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
[TBL] [Abstract][Full Text] [Related]
14. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
15. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z
Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
17. Apocynin-loaded PLGA nanomedicine tailored with galactosylated chitosan intrigue asialoglycoprotein receptor in hepatic carcinoma: Prospective targeted therapy.
Anter HM; Aman RM; Othman DIA; Elamin KM; Hashim IIA; Meshali MM
Int J Pharm; 2023 Jan; 631():122536. PubMed ID: 36572262
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cytotoxic and apoptotic potential in hepatic carcinoma cells of chitosan nanoparticles loaded with ginsenoside compound K.
Zhang J; Wang Y; Jiang Y; Liu T; Luo Y; Diao E; Cao Y; Chen L; Zhang L; Gu Q; Zhou J; Sun F; Zheng W; Liu J; Li X; Hu W
Carbohydr Polym; 2018 Oct; 198():537-545. PubMed ID: 30093032
[TBL] [Abstract][Full Text] [Related]
19. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
20. Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma.
Huang M; Liu J; Fan Y; Sun J; Cheng JX; Zhang XF; Zhai BT; Guo DY
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127219. PubMed ID: 37802456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
